

Healthcare on the

go



MYCARE MEDTECH INC.
Executive Summary | July 2021

THE FUTURE OF HEALTHCARE IS TELEMEDICINE

“In a few years, the idea of receiving medical treatment exclusively at a doctor’s office or hospital will seem quaint.” Harvard Business Review.

All areas of medicine are incorporating virtual care (telemedicine) to provide convenient patient access to physicians, nurses, and healthcare coordinators; the trend is growing at a tremendous rate. The ability to blend traditional medicine with natural and lifestyle options has finally emerged. In fact, a total approach to healthcare leads to better outcomes.

Building on its experience and proprietary platform, MMI has developed 7 virtual specialty clinics supported by national and international partnerships, monitoring and patient concierge teams and is developing its own proprietary therapeutic products to take a leading position in a major new industry.

This acceptance and adoption of telemedicine and advances in medical assessment apps and secure communication tools provides tremendous opportunities for condition-specific assessment, treatment and monitoring. Patients have come to accept virtual visits as the future of medicine. They expect new and varied services; through telemedicine, greater optionality will be available to them to help manage chronic and lifestyle conditions.

Success stories are being written almost monthly as new healthcare and lifestyle companies emerge to take advantage using their expertise and introducing new products and services. Examples of these are companies such as Noom, Charlotte’s Web, etc. MMI has quickly risen to become a major player in this revolution space and is now poised to offer an exciting portfolio of new medical and lifestyle solutions with a highly integrated approach.



Source: <https://www.fshealth.com/blog/29-statistics-about-telemedicine-healthcare> office

Source: <https://www.hcinnovationgroup.com/clinical-it/news/13030029/report-telehealth-market-estimated-to-reach-195b-by-2025>

Source: <https://pubmed.ncbi.nlm.nih.gov/16356311/>

WHAT IS THE POTENTIAL?

The pandemic has added to the already pressing issues of timely and convenient access to care in Canada, while creating an opportunity to deliver medical services beyond episodic and primary care. **Canadians are seeking more online solutions to healthcare concerns.**

Demographic considerations, including the introduction of Millennial consumers, mandates that the antiquated Healthcare industry change its' delivery of services to an On-Demand model.

Today's consumers prefer efficient and secure access to their healthcare requirements leveraging technology commonly used in other areas of their life including work and school.

Canada does not yet offer a **technology driven, fully integrated end-to-end healthcare as a service model** to its' Citizens.

As existing organizations look to pivot to satisfy this demand, only companies with proven capabilities and experience in this space will be successful. The current market is fractured with companies providing component programs forcing the client to search for relevant services.



ABOUT MYCARE MEDTECH INC. (MMi)

MyCare MedTech Inc. (MMi) has been utilizing leading edge communication technology and licensed medical providers to deliver virtual medical consultations from coast to coast since 2016.

MMi offers services for individuals, families, post-secondary student organizations, group benefits providers, third party administrators, pharmacies (retail), small and medium size businesses and associations. **Current membership exceeds 83,000.**

MMi is also developing virtual clinics that cover both medical and lifestyle concerns while providing proprietary and distributor products through an intuitive eCommerce portal. MMi's flexible and comprehensive platform can accommodate new products and programs without significant programming costs.

MMi will use its proprietary platform combined with new programs to transition to a full-service telemedicine company. Capitalizing on its telemedicine experience and existing personnel, MMi can quickly deploy **an eCommerce component with repeat sales and ongoing fee-based monitoring** for a variety of technologies and health issues.

UNIQUE POSITIONING WITH GOeVISIT INTEGRATION

MMi's branded telemedicine service, GOeVisit, can diagnose, treat and prescribe for more than 450 minor illnesses ranging from coughs, colds and flu to general medical concerns, minor injuries and pediatric care, all through an intuitive mobile application. GOeVisit treats about 75% of the issues normally seen by in-person visits to a family physician.

At present, **MMi is the only integrated virtual consultation company in Canada, with combined capabilities to make it uniquely positioned as Canada's leading telemedicine solution offering condition-specific medical services coast-to-coast.**

MMi possesses a distinct advantage over potential competitors through an integrated approach that incorporates both medical and lifestyle monitoring, recommendations, prescriptions, proprietary products, and services. Current market research indicates it will likely be at least two years before competition develops in this market.

MMi is uniquely positioned to be the **first to market** nationally. The integration of technologies for **GOeVisit** is complete and the first **virtual clinics** were launched in May 2021. The balance of the virtual clinics and the **eCommerce portal** will be introduced from July to December 2021.

HOW IT WORKS

Licensed medical providers conduct clinical interviews by phone or via face-to-face technology to discuss and confirm a diagnosis and treatment plan. A comprehensive after-visit summary of the consult, diagnosis and treatment plan is forwarded via a privacy protected, secure link to the client and to their family physician, if requested. Required prescriptions are sent automatically to the client's pharmacy of choice. Prescriptions are limited to non-controlled medications. Over-the-counter medications and home remedy suggestions are included in the after-visit summary.

MMi patient concierge staff follow up with the client within 48 hours to confirm their health situation is improving. If treatment is not initially effective, the client may receive, without cost, an additional consultation or recommendation for an in-person visit.



PRIVACY AND SECURITY OF DATA

GOeVisit adheres to all PHIPA, HIPAA, PHI and PIPEDA guidelines and regulations. All client data and medical information is processed and stored in a HIPAA compliant environment in Montreal, QC, Canada and hosted by Amazon Web Services (AWS.). All transmission of data and information is secured and encrypted using the same technology used by banking institutions.

VIRTUAL SPECIALITY CLINICS

MMi's flexible software platform supports the Company's intention to readily deploy several integrated specific condition virtual clinics. These clinics provide clients with options to treat and monitor specific personal needs. Clients can access a licensed medical provider for personal health issues, medical file storage, including client notes, monthly or bi-monthly monitoring and regular communication with MMi's Patient Concierge team. The Virtual Clinics are grouped into two (2) categories:

General Use Clinics:

- Online consultation for over 450 non acute medical issues including non-controlled prescriptions
- Mental Health Assessment and Treatment
- Online Physio
- Travel Clinics – including COVID-19 testing sites

Membership Only Clinics:

- Dermatology – including prescriptions, skin care and cosmetic products
- Chronic Pain Management – prescriptions and CBD therapeutics products
- Weight Loss – prescriptions and CBD products
- Anxiety/Depression – prescriptions and CBD products
- Cognitive Degeneration – prescriptions and CBD products
- CBD products – licensed genetics with specific cannabinoid profile supporting the above clinics
- eCommerce – membership discount and free delivery




THE POWER OF CANNABIDIOL (CBD)

CBD, a non-psychoactive cannabinoid found in CBD, has proven to be an effective therapy to treat a wide range of conditions from PTSD and anxiety, to MS and epilepsy, to chronic pain and significant neurodegenerative medical conditions.

Scientific research underscores CBD's potential as a treatment for a wide range of conditions including:

- Arthritis
- Anxiety
- Addiction
- Multiple Sclerosis
- Chronic pain
- Schizophrenia
- Cancer
- Post-Traumatic Stress Disorder
- Depression
- Antibiotic resistant infections
- Epilepsy
- Other neurological disorders
- Cognitive degeneration
- Weight management



CBD has demonstrable neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated by research centers worldwide. Evidence suggests that CBD is safe even at high doses.

Cannabinoids and terpenes (i.e., additional medically significant molecules found in CBD) work simultaneously to boost and modulate their combined effects in the body's endocannabinoid system.

60+ cannabinoids have been identified in CBD. Cannabidiol (**CBD**), cannabigerol (**CBG**) cannabichromene (**CBC**) and cannabiol (**CBN**) are believed to have the greatest therapeutic benefits to date.

The CBD-derived CBD market is expected to hit \$22 billion by 2022. (<https://www.bnnbloomberg.ca/cbd-market-set-to-take-off>)

SUPERIOR GENETICS = SUPERIOR OIL = SUPERIOR PRODUCTS

MMi is partnering with a CBD research company to secure specific genetic material with the appropriate cannabinoid and terpene profile to produce oils for its proprietary product offerings.

The CBD oils have:

- The highest known concentration of CBD in the market
- A high yield of therapeutic ancillary cannabinoids
- A full spectrum of cannabinoids, terpenes and essential oils to magnify the intrinsic benefits
- Specific product formulations, monitored progress and recommendations from qualified medical professionals

These oils will be used to create MMi products for skin care, cosmetics, anxiety and depression including PTSD, cognitive degeneration, including Alzheimer's and dementia, neurological issues including Parkinson's, weight loss, pain management including sports injuries, arthritis, etc. The treatment effectiveness of these proprietary therapies underpins MMi's competitive advantage in the telehealth space.

MMi partners will grow the plants in a controlled production facility, extract the oil and produce the appropriate condition specific CBD. Each product contains negligible THC and is therefore non-psychoactive.

MMi will start production in Canada in the fall of 2021 with limited availability of product by January 2022.

Contingent on legislation, MMi expects to be able to produce CBD oils for the same conditions in the US. The Company plans on launching the US subsidiary, with the same clinics other than the medical consultation for minor illnesses, in the second quarter of 2022.

INTRODUCING MMI THERAPEUTICS

Seeing the necessity and urgency for a trusted name in virtual medical consultations, CBD-based therapeutic product recommendations and CBD-based therapeutic products, MMi Therapeutics has been formed as a division of MyCare MedTech Inc (MMi). MMi has in-depth experience in telemedicine, health insurance and employee benefit programs, and has been actively involved in CBD research and testing for therapeutic purposes.

MMi Therapeutic's vision is to quickly become the trusted choice for evidence-based research of CBD for therapeutic purposes, clinical-based virtual consultations and proven CBD-based therapeutic formularies to treat four (4) broad conditions:

- Chronic pain, including pain that depends on the use of opioids for relief, e.g., fibromyalgia, osteoarthritis, short-term recovery/surgery, sports injuries
- Stress, anxiety and/or PTSD
- Dermatological including skin care and cosmetics
- Weight Management

All CBD-based therapeutic products on the MMi US site will be tested and will have less than 0.3% THC, making it legal to transport across state lines in the US.

WHO IS MMI THERAPEUTICS TALKING TO?

The primary audience for MMI Therapeutics is B2C and B2B2C, and specifically individuals who:

- Are caring for someone or care about someone with a chronic condition (e.g., arthritis, cancer pain management, chronic fatigue, fibromyalgia, sports injury, rheumatism, and other inflammatory diseases), stress/anxiety/PTSD, skin conditions and/or weight management issues.
- Have been diagnosed with a chronic condition, are experiencing stress/ anxiety/PTSD, have issues with weight control and/or have episodic or chronic skin conditions and are looking for something that can treat and/or assist in the management or prevention of the malady.
- Have a genetic predisposition to a chronic condition, disease and/or stress/ anxiety/PTSD.
- Are concerned that they are symptomatic of a chronic condition, stress/anxiety/PTSD.
- Rely on their bodies for work.
- Are weekend warriors.

Due to the care factor, the target audience is focused on a broad demographic range; MMi is focusing on the millennial and boomer markets, particularly those dealing with chronic physical and anxiety and depression issues. This audience likely skews female, with a wide age range: 35+; old enough to have aging loved ones or children with physical/mental health issues, epilepsy, and mature enough to want to help them, or old enough to be personally dealing with episodic or chronic physical/mental health issues.

These individuals come from all socio-economic streams and are conscious of what they are putting into their bodies. They are seeking natural-based alternatives to Western-based treatments as the latter has not provided the results they were initially seeking.

The majority of this market would strongly consider using CBD-based therapeutic patches, gel caps, fast-acting dissolvables, creams, balms, oils and/or tinctures. They are less likely to be comfortable smoking or vaping the product.

There are currently 19 million people in Canada and 140 million people in the US who have a medical condition treatable with a CBD-based therapeutic product.

The secondary audience for MMI Therapeutics is B2B white labelling with established partners including national employee benefits companies.

The tertiary audience for MMI Therapeutics is B2Medical, specifically doctors and holistic practitioners, for whom MMI would like to become a trusted source of evidence-based research of CBD for therapeutic purposes.

HOW WILL THESE MARKETS FIND MMI THERAPEUTICS?

MMI's current member database, and broad network of strategic partners gives access to a market of more than 5 million Canadians in Canada alone.

The Virtual Specialty Clinics and MMI Therapeutics will be rigorously marketing through existing and new cross marketing agreements, paid digital media, through social media network and via ongoing marketing and public relations.

WHAT ABOUT THE COMPETITION?

There appears to be a considerable amount of competition in the therapeutics space. Many companies are doing (or claiming to do) what MMI Therapeutics is initiating. New competition will also be continually emerging. There's so much noise out there that stressing MMI's key differentiators will be vital (the trusted choice for evidence-based research of CBD for therapeutic purposes, clinical-based virtual consultations and proven CBD-based therapeutic formularies to treat chronic pain, stress/anxiety/PTSD, dermatological issues and weight management).

A significant competitive factor will be US-based therapeutic CBD and cannabis companies already established and operating where legal in the US that will expand to Canada. Many have done so already or are planning to. Investing in promotion will be key in order to stand out in a very crowded market (many competitors such as NamasteMD are already doing this).

WHAT IS THE MMI THERAPEUTICS PROCESS?

MMI Therapeutics will provide an end-to-end user experience where subscribers will:

- Register for a virtual clinic (free)
- Complete a 5-7 minute assessment to start a logic tree about symptoms/severity of symptoms
- Complete a comprehensive after-visit summary is provided to client
- Pay membership fee (~ \$8/month for a family)
- Receive medical consultation via Facetime/Skype
- Order recommended product on website (can only purchase product on MMI post-consult)
- Be able to repurchase product via follow-up consult

MMI provides follow up and feedback to ensure the recommended formulary and strength are effective--an interactive app will allow the client to track efficacy.

Note: Education and product catalogue will be free to view BUT to purchase product, you will need to register, complete the assessment, pay the membership fee and receive a virtual consultation.

WHAT MAKES MMI THERAPEUTICS THE TRUSTED SOURCE IN CBD-BASED THERAPEUTIC PRODUCTS?

- The MMI team consists of doctors, scientists, product specialists with vast experience in research and trials of CBD for therapeutic purposes.
- Clinical interview/virtual consultation done by licensed medical practitioners and nurse practitioners who have certification and training in CBD-based therapeutic products.
- Membership ensures more clinical data — members must return so that medical staff can measure the efficacy, adjust dosage and/or make recommendations moving forward.
- MMI Therapeutics only works with licensed cultivators (Canada) and licensed growers (US) growing CBD purely for therapeutic use — those who produce strains with low THC and high potency that can be put into pills, gel caps or fast-acting dissolvable.
- All MMI formularies, whether recommended or branded, are tested and have less than 0.3% THC.
- MMI team uniquely experienced to enter this market based on previous work in telemedicine, health and employee benefit services.

What is the brand character?

- Trustworthy (the ultimate authority in CBD-based therapeutic products)
- Experienced (the expert; research/evidence-based)
- Knowledgeable (authoritative, factual, diligent)
- Compassionate (non-judgmental and nurturing)
- Caring (approachable)
- Innovative (desire to change things for the better through scientific research)
- Visionary (innovative and transformative — ahead of mainstream thinking)

And the tone of voice?

- Clinical (professional and research-based) but approachable (warm and not intimidating)
- Engaging (educational without lecturing)
- Credible, so trustworthy (we are the experts)
- Authoritative (we know what we're talking about) but humanist (so not paternalistic)
- Fresh and strong (this is an emerging field and MMI Therapeutics is leading the way)

Brand Champion?

An example of a brand champion or a celebrity that summed up the brand, Dr. Andrew Weil was identified as one example. He has all the credentials of a Western-trained doctor, but also has a huge interest and expertise in nutraceuticals, seeking plant-based solutions for patients to enhance or replace what they're already doing. Dr. Weil is a researcher, published doctor, educated, knowledgeable, experienced, trustworthy and empathetic — so he fits the bill.

MMi is uniquely experienced to position MMI Therapeutics as the go-to trusted source for CBD-based therapeutic products as a result of the current businesses, the team’s collective experience, their values and skills and the fact that they already have a blueprint that they can be applied.

PROPRIETARY NON-CBD THERAPEUTICS AND SUPPORTING PRODUCTS


MMi is partnering with a seasoned compounding laboratory to formulate, test, manufacture and delivery proprietary products and therapeutics. The laboratory has experience and is a subsidiary of an online prescription delivery company with national programs. MMi intends to leverage this partnership to develop a line of Nutraceuticals to support patients in its Specialty Clinics who may not want to initially use CBD products.

PARTNERSHIPS **

MMi has also entered into agreements to support several of the virtual clinics:

- Lightwell Therapy and Tranquility (depression/anxiety)
- Derm Café (dermatology)
- Curves International – weight management and wellness
- DrugSmart Canada – prescription delivery and non CBD Product formulation
- Alliance Pharmacy – prescription delivery
- Canadian Travel Clinics – Travel and COVID Testing
- W2 BioPharma – CBD genetics and oil production
- Huma+ Gestion Inc.
- MedExtra Inc.

** These established networks contain over 5 million clients and employees



EXPANSION INTO USA

US expansion will begin in Arizona, California and Washington and extend to Texas and Florida. These states have the proper demographics and established CBD legislation to provide a substantial membership base.

MMi will partner with a US-based virtual medical consultation services for minor illness consultations, avoiding the excessive costs of licensing state by state.

TARGET MARKETS

MMi is focusing on the B2B and B2B2C markets through its established employee benefits networks.

The value proposition to employers includes reduced absenteeism and reduced prescription drug costs, offsetting any costs to corporations.

Targeting corporations provides volume business and a dedicated payor without the need for large investments in advertising. Mmi intends to aggressively market to Canadian companies.

Each client and/or employee of these companies provides an opportunity to market clinic memberships for the virtual clinics. Many of the products and services provided will be eligible for reimbursement through the employer's extended medical benefits plan.

A secondary focus is on individual Canadians through membership sales on an individual basis. Mmi will focus programs targeted to the Boomer and Millennial demographics.

MARKETING PLAN

Major marketing programs including a new product launch strategy have been developed for corporate clients and the General Public.

The Company is contracting qualified direct sales personnel in major markets and targeting Third Party Benefits Administrators (TPAs) and an existing employee benefits broker network.


Experience has shown that a direct marketing approach to large and medium sized companies is effective when offering new benefit options. Mmi will implement an aggressive direct marketing approach emphasizing the convenience and positive benefits to corporations while decreasing absenteeism and improving their bottom line.

MMi believes the announcement of the GOeVisit virtual clinic programs will garner considerable media attention and will contract an experienced PR firm to maximize exposure. Online Marketing, Social Media and member Association programs will be pursued as part of the overall communication and marketing plan while focusing on the corporate market.




Third Party Administrators and Broker/Agent Network: MMI's parent organization already deals with 6 TPAs and has developed a Broker network with over 2 million Canadian employees. MMI, with cooperation of its agents and plan sponsors, intends to mine this network as its primary marketing initiative.



REVENUE STREAMS



FIVE-YEAR FINANCIAL PROJECTIONS



USE OF PROCEEDS



*Equity Investment

EXECUTIVE TEAM



Jim Viccars – President | An industry disruptor and creator of innovative and impactful ‘firsts’ including the first private hospital in Canada; private not-for-profit assisted living facility in Alberta; medical waitlist insurance program Canada; Mayo Clinic insurance and employee benefit programs uniquely designed for Canadians; and GOeVisit 24/7 virtual medical services platform.



Liz Bryant - Chief Executive Officer | Liz co-founded MMI and launched GOeVisit and the MyCare family of insurance products in Canada. Liz is a former “C” level executive to two of Canada’s largest charities. Liz is an operations architect and collaborator and is a published author.



Medical Advisory Group | MMI works with a cadre of physicians with in-depth training and experience in family medicine, chronic pain, sports injuries, dermatology, mental health concerns and more.



Rob Shaw, Chief Technology Officer | 20+ years of software and systems development experience and a broad range of programming knowledge. Original architect of GOeVisit’s robust technology.



Aaryn Bryant – Director of Operations | Extensive knowledge of systems and 15 years’ experience in national startups, communications, advertising, marketing and social media.



Lisa Delmars, Clinic Advisor | An accomplished entrepreneur and business development specialist with more than 18 years’ experience in private healthcare and clinic management.

MEDICAL ADVISORY

Dr. Simon Sutcliffe

Dr. Sutcliffe is the past President and CEO of the British Columbia Cancer Agency (BCCA), and of the Ontario Cancer Institute (OCI) and Princess Margaret Hospital. Dr. Sutcliffe is currently the, Chair of the Canadian Partnership against Cancer.

Dr. Gordon Brock

Dr. Brock is one of Canada's longest-serving rural physicians and is specialized in chronic disease management, mental health, wound care and pain/addiction services. He is Medical Director of MedExtra Corporation of Canada, a Montreal-based company providing medical and disability management to Corporations nationally.

Dr. Michael Wilkinson

Dr. Wilkinson practices sports and rehab medicine in Vancouver. He holds the CASM Diploma in Sports Medicine and an MBA, Queens University. He is the CMO for the Canadian Rowing team, a team physician for the Vancouver Canucks, Canadian and BC senior Rugby Teams.



INVESTMENT OPPORTUNITY

\$10 Million CAD total target investment

- \$0.35/share for founding partners
- \$100,000 minimum investment

EXIT DATE

Public listing planned for early 2022.

SUMMARY

There is considerable excitement around the potential to use digital and virtual technology to increase healthcare delivery efficiency, control or reduce costs and allow the patient to take a proactive role in their healthcare decisions.

MMi believes combining medical consultation with monitoring and specific CBD and non CBD therapeutics, medical devices, advice and recommendations will set the Company apart from competition and provide considerable market success.


Smartphone apps offer significant opportunities for program enhancement and revenue. Millennials prefer to access services advice and to buy products through these apps.

Revenue streams, particularly those through membership clinics will grow to significant sales by providing quality programs and repeat sale products.

Corporate recognition is enhanced by cooperative programs, extensive corporate reach through employee benefits networks and social media marketing.

CONTACT

MyCare MedTech Inc.
Jim Viccars, President
403-703-7488
jim@goevisit.com



READER'S ADVISORY AND FORWARD-LOOKING INFO

This corporate Business Plan (the "Plan") has been prepared by management of MyCare MedTech Inc. ("MMi", "MyCare", the "Company" or the "Corporation") based on public information and the Corporation's confidential information. This Plan is for information purposes only and is being made available on a confidential basis solely to enable the prospective investor to evaluate the securities of the Corporation (the "Securities"). This Plan does not constitute an offer to sell to any person, or a general offer to the public of, or the general solicitation from the public of offers to subscribe or purchase, any of the Securities. Any unauthorized use of this Plan is strictly prohibited. Distribution or copying of this Plan, in whole or in part in any medium, to any person other than the prospective investor is prohibited without the prior written consent of the Corporation. The information contained in these slides, the Plan made to you verbally and any other information provided to you (in writing or otherwise) in connection with the Corporation and its business (the "Plan Materials") is subject to updating, completion, revision, verification and amendment without notice which may result in material changes.

The Plan Materials are not intended to provide financial, tax, legal or accounting advice and do not purport to contain all the information that a prospective investor may require. Each prospective investor should perform and rely on its own investigation and analysis of the Corporation and the terms of any offering of the Securities, including the merits and risks involved, and are advised to seek their own professional advice on the legal, financial and taxation consequences of making an investment in the Corporation.

No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this Plan, and any representation to the contrary is an offence. Neither the Corporation nor the agent of the Corporation makes any representation or warranty, express or implied, and assumes no responsibility for the accuracy or completeness of the information contained in this Plan or any other oral or written communication transmitted to prospective investors, and nothing contained in this summary is, or shall be relied upon as, a promise or representation by the Corporation or the agent of the Corporation as to the past or future performance of the Corporation.

The Corporation does not undertake to provide any additional further information or to enter into negotiations regarding the investment opportunity to which these Plan Materials relate. The Corporation retains the right, at any time, to terminate any discussions or negotiations with prospective investors. In the event of such termination, the Corporation will not be under any obligation to disclose the reasons for such termination nor will they have any liability to any recipient thereof for any costs whatsoever incurred in the consideration of the information contained in these Plan Materials.

Certain statements contained in this Plan are forward-looking statements. These forward-looking statements are not based on historical facts but rather on the expectations of management of the Corporation regarding the resulting company's future performance. All statements, other than statements of historical fact, may be forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", "predict", "propose", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar expressions.

Although the Corporation believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Corporation can give no assurance that they will prove to be correct, and actual results, performance or achievement could differ materially from those expressed in, or implied by, these forward-looking statements.

Forward-looking statements contained in this Plan include, but are not limited to, statements with respect to the Corporation's business strategy, the market in which the Corporation operates; the ability of the Corporation to successfully integrate businesses; the timing and nature of equity offerings to be completed by the Corporation; the Corporation's potential revenue; the ability of the Corporation to successfully complete mergers and acquisitions; the ability of the Corporation to realize on the potential of target companies; and other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Forward-looking statements contained in this Plan reflect the current beliefs and assumptions of the Corporation's management based on information in its possession as of the date of this Plan. Readers are cautioned that the foregoing list is not exhaustive. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this Plan are made as of the date of this Plan and the Corporation does not undertake and is not obligated to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless so required by applicable securities law.